Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5170268 | 1.00 | SMN1; SMN2 (0.39) | SMN1; SMN2TDP1OPRK1OPRD1OPRM1 | |
| SCHEMBL5171001 | 0.97 | OPRK1 (0.38) | SMN1; SMN2TDP1OPRK1OPRD1OPRM1 | |
| SCHEMBL5171005 | 0.97 | OPRK1 (0.38) | SMN1; SMN2TDP1OPRK1OPRD1OPRM1 | |
| SCHEMBL5169497 | 0.95 | SMN1; SMN2 (0.38) | SMN1; SMN2TDP1OPRK1OPRD1OPRM1 | |
| SCHEMBL5171484 | 0.95 | SMN1; SMN2 (0.38) | SMN1; SMN2TDP1OPRK1OPRD1OPRM1 | |
| SCHEMBL5170386 | 0.94 | SMN1; SMN2 (0.40) | SMN1; SMN2TDP1OPRK1OPRD1OPRM1 | |
| SCHEMBL5169907 | 0.94 | SMN1; SMN2 (0.40) | SMN1; SMN2TDP1OPRK1OPRD1OPRM1 | |
| SCHEMBL5170684 | 0.91 | CCR6 (0.38) | SMN1; SMN2OPRK1OPRD1OPRM1SLC6A2 | |
| SCHEMBL5171017 | 0.91 | CCR6 (0.38) | SMN1; SMN2OPRK1OPRD1OPRM1SLC6A2 | |
| SCHEMBL5171968 | 0.90 | SLC6A2 (0.42) | OPRK1OPRD1OPRM1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322590-B1 | 5-AMINO-1-PENTENE-3-OL SUBSTITUTED DERIVATIVES | GRUENENTHAL GMBH (DE) | 2007-05-02 | — | — | EP | claimed |
| US-6815443-B2 | CARBOCYCLIC OXY AMINES SUCH AS 2-BENZYLIDENE-6-DIMETHYLAMINO METHYLCYCLOHEXANONE, USED AS ANALGESICS | GRUENENTHAL GMBH (DE) | 2004-11-09 | — | — | US | claimed |
| US-20030220390-A1 | 5-Amino-1-pentene-3-ol substituted derivatives | GRUENENTHAL GMBH (DE) | 2003-11-27 | — | — | US | claimed |
| US-6815443-B2 | CARBOCYCLIC OXY AMINES SUCH AS 2-BENZYLIDENE-6-DIMETHYLAMINO METHYLCYCLOHEXANONE, USED AS ANALGESICS | GRUENENTHAL GMBH (DE) | 2004-11-09 | — | — | US | disclosed |
| US-20030220390-A1 | 5-Amino-1-pentene-3-ol substituted derivatives | GRUENENTHAL GMBH (DE) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220390-A1 | 5-Amino-1-pentene-3-ol substituted derivatives | ALOX5, PGA5, ANXA5 | SMN1; SMN2 4219/4885TDP1 3162/4885OPRK1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.